This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Figueiredo, J. C. Articles by Ozcelik, H. Search for Related Content PubMed PubMed Citation Articles by Figueiredo, J. C. Articles by Ozcelik, H.

Polymorphisms XRCC1-R399Q and XRCC3-T241M and the Risk of Breast Cancer at the Ontario Site of the Breast Cancer Family Registry

¹ Fred A. Litwin Centre for Cancer Genetics, ² Division of Epidemiology and Biostatistics, ³ Department of Pathology and Laboratory Medicine, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, ON, Canada and Departments of ⁴ Public Health Sciences and ⁵ Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada

Requests for reprints: Hilmi Ozcelik, Fred A. Litwin Centre for Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Room 992A, 600 University Avenue, Toronto, ON M5G 1X5. Phone: (416) 586-4996; Fax: (416) 586-8869. E-mail: ozcelik{at}mshri.on.ca

This study investigates the role of two nonsynonymous single nucleotide polymorphisms in DNA repair genes, X-ray repair cross-complementing group 1 (XRCC1)-R399Q and X-ray repair cross-complementing group 3 (XRCC3)-T241M, in breast cancer. Incident cases of invasive breast cancer in Caucasian women [n = 402, mean age = 45.7 (SD = 6.2) years] and female Caucasian controls [n = 402, mean age = 45.2 (6.5) years] frequency matched on 5-year age intervals were identified from the Ontario Familial Breast Cancer Registry. No evidence for a main effect of the XRCC1-R399Q genotype on breast cancer risk was observed. Estimates of risk for a family history (FH) of breast cancer compared with no FH differed by XRCC1-R399Q genotype (P value for interaction = 0.001). Homozygote XRCC1-399 R/R individuals and FH+ were at a 2.92-fold [95% confidence interval (95% CI) = 1.47–5.79] increased risk of disease compared with FH– individuals; the estimate of risk increased for R/Q heterozygotes with FH+ [odds ratio (OR) = 3.85, 95% CI = 1.94–7.65] but not for Q/Q homozygotes with FH+ (OR = 0.54, 95% CI = 0.20–1.47) compared with homozygous R/R and FH– individuals. A marginal positive association for XRCC3-241 M/M compared with T/T genotype was found (OR = 1.44, 95% CI = 0.94–2.19), but the heterozygous T/M was not associated with an increase in risk (OR = 0.96, 95% CI = 0.71–1.32). There was also some evidence for a combined effect of body mass index and XRCC3-T241M on estimates of risk. Our results suggest that these polymorphisms may influence breast cancer risk by modifying the effect of risk factors such as FH. There is a need for further study into the role of these polymorphisms as effect modifiers.

This article has been cited by other articles:

				J. Stone, L. C. Gurrin, G. B. Byrnes, C. J. Schroen, S. A. Treloar, E. J.D. Padilla, G. S. Dite, M. C. Southey, V. M. Hayes, and J. L. Hopper Mammographic Density and Candidate Gene Variants: A Twins and Sisters Study Cancer Epidemiol. Biomarkers Prev., July 1, 2007; 16(7): 1479 - 1484. [Abstract] [Full Text] [PDF]

				P. Bhatti, D. M. Church, J. L. Rutter, J. P. Struewing, and A. J. Sigurdson Candidate Single Nucleotide Polymorphism Selection using Publicly Available Tools: A Guide for Epidemiologists Am. J. Epidemiol., October 15, 2006; 164(8): 794 - 804. [Abstract] [Full Text] [PDF]

				The Breast Cancer Association Consortium Commonly studied single-nucleotide polymorphisms and breast cancer: results from the Breast Cancer Association Consortium. J Natl Cancer Inst, October 4, 2006; 98(19): 1382 - 1396. [Abstract] [Full Text] [PDF]

				A. R. Lindh, S. Rafii, N. Schultz, A. Cox, and T. Helleday Mitotic defects in XRCC3 variants T241M and D213N and their relation to cancer susceptibility Hum. Mol. Genet., April 1, 2006; 15(7): 1217 - 1224. [Abstract] [Full Text] [PDF]

				B. F. Pachkowski, S. Winkel, Y. Kubota, J. A. Swenberg, R. C. Millikan, and J. Nakamura XRCC1 Genotype and Breast Cancer: Functional Studies and Epidemiologic Data Show Interactions between XRCC1 Codon 280 His and Smoking. Cancer Res., March 1, 2006; 66(5): 2860 - 2868. [Abstract] [Full Text] [PDF]

				Y. Zhang, P. A. Newcomb, K. M. Egan, L. Titus-Ernstoff, S. Chanock, R. Welch, L. A. Brinton, J. Lissowska, A. Bardin-Mikolajczak, B. Peplonska, et al. Genetic polymorphisms in base-excision repair pathway genes and risk of breast cancer. Cancer Epidemiol. Biomarkers Prev., February 1, 2006; 15(2): 353 - 358. [Abstract] [Full Text] [PDF]

				R. C. Millikan, J. S. Player, A. R. deCotret, C.-K. Tse, and T. Keku Polymorphisms in DNA Repair Genes, Medical Exposure to Ionizing Radiation, and Breast Cancer Risk Cancer Epidemiol. Biomarkers Prev., October 1, 2005; 14(10): 2326 - 2334. [Abstract] [Full Text] [PDF]

				Z. Hu, H. Ma, F. Chen, Q. Wei, and H. Shen XRCC1 Polymorphisms and Cancer Risk: A Meta-analysis of 38 Case-Control Studies Cancer Epidemiol. Biomarkers Prev., July 1, 2005; 14(7): 1810 - 1818. [Abstract] [Full Text] [PDF]

				P. M. Webb, J. L. Hopper, B. Newman, X. Chen, L. Kelemen, G. G. Giles, M. C. Southey, G. Chenevix-Trench, and A. B. Spurdle Double-Strand Break Repair Gene Polymorphisms and Risk of Breast or Ovarian Cancer Cancer Epidemiol. Biomarkers Prev., February 1, 2005; 14(2): 319 - 323. [Abstract] [Full Text] [PDF]